Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the world. It’s estimated that roughly 25 percent of people in the United States have fat deposition in the liver. Understanding how certain factors affect the progression of fatty liver disease — such as diet and gut bacteria — allows us to tailor therapies to individuals at a highest risk for disease progression. We offer the latest clinical trials of promising therapies related to fatty liver disease.
Dedicated to advancing treatment, UChicago Medicine has an internationally-recognized group of investigators with specific interests in the role gut bacteria and intestinal inflammation plays in fat build up in the liver. We also have researchers with advanced experience utilizing mouse models to study fatty liver disease.
At the University of Chicago Medicine, we’re committed to advancing discoveries that transform our patients’ lives and expand our physicians’ knowledge. Explore our active clinical trials.
Find a Clinical Trial